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Background. The knowledge is still sparse about patient related factors, influencing oral anticoagulation therapy (OAC) rates, in
stroke patients with atrial fibrillation (AF). Aims. To assess the use of OAC in ischemic stroke patients diagnosed with AF and to
identify patient related factors influencing the initiation of OAC. Methods. In the nationwide Danish Stroke Registry we identified
55,551 patients admitted with acute ischemic stroke from 2003 to 2011. Frequency analysis was used to assess the use of OAC in
patients with AF, and logistic regression was used to determine independent predictors of OAC. Results.1 7 . 1 %( 𝑛 = 9,482)o f
ischemic stroke patients had AF. OAC prescription rates were increasing, and in 2011 46.6% were prescribed OAC, 42.5% had a
contraindication, and 3.7% were not prescribed OAC without a stated contraindication. Younger age, less severe stroke, and male
gender were positive predictors of OAC, while excessive alcohol consumption, smoking, and institutionalization were negative
predictors of OAC (𝑃 values < 0.05). Conclusions. Advanced age, severe stroke, female gender, institutionalization, smoking, and
excessive alcohol consumption were associated with lower OAC rates. Contraindications were generally present in patients not in
therapy, and the assumed underuse of OAC may be overestimated.
1. Introduction
Atrialfibrillation(AF)isanimportantriskfactorforischemic
stroke[1,2].Thedetectionofeitherpermanentorparoxysmal
AFhasanimmediateimpactontreatmentandriskreduction
in stroke patients [3]. It is well known that oral anticoagulant
therapy (OAC), until 2011 exclusively in Denmark with
vitamin K antagonists (VKA), is indicated as secondary
prevention [4]a n dl o w e r st h er e l a t i v er i s ko fr e c u r r e n t
stroke by two thirds [5, 6]. Nevertheless, it has repeatedly
been alleged that AF patients do not receive OAC as often
as it is clinically indicated [7–10]. It has been suggested
that physicians may overestimate bleeding risk from OAC
and underestimate its benefits in stroke prevention [11, 12].
However,theknowledgeaboutmotivations,includingpatient
related factors, driving clinical decision-making, and thus
influencing therapy rates, is still sparse.
TheaimofstudywastoassesstheuseofO A Cinischemic
stroke patients diagnosed with AF and to identify patient
related factors influencing the initiation of OAC in possible
eligible patients, based on the nationwide Danish Stroke
Registry, in the period from 2003 to 2011.
2. Methods
2.1. The Danish Stroke Registry. The Danish National Health
Service provides tax-supported health care for all citizens,
including access to hospital care with no costs. All medical
emergencies, including stroke, are exclusively treated at pub-
lichospitals,andthevisitationisbaseduponcatchment’sarea
a n dd i a g n o s e s .Th eD a n i s hS t r o k eR e g i s t r y( D A P ) ,f o r m e ra
partoftheDanishNationalIndicatorProject,isanationwide
stroke registry initiated in 2003. DAP monitors and improves2 Thrombosis
the quality of care provided by hospitals by benchmarking.
Evidence based standards, indicators, and prognostic factors
are used. Data is collected prospectively in all 35 stroke units
in the country by health care specialists, in the stroke units,
through a mandatory, standardized registration form [13];
a u d i t sa r ep e r f o r m e d .Th e s es t r o k eu n i t ss e r v et h ee n t i r e
Danish population of approximately 5.5 million inhabitants.
The coverage of stroke units is complete, and data on patients
with concurrent illnesses causing admission to other depart-
ments is also collected systematically. All patients (≥18 years)
admitted to Danish hospitals with acute stroke according
to the World Health Organization criteria are eligible for
inclusion in DAP. Only patients with a final diagnosis of
intracerebral haemorrhage, cerebral infarction, and stroke
not specified as haemorrhage or infarction are recorded in
the registry. Computer tomography (CT) and/or magnetic
resonance imaging (MRI) scans on the day of admission
are quality indicator as they differentiate cerebral infarction
and intracerebral haemorrhage and exclude, for example,
subdural hematoma or tumour. In 2011, 85% of all acute
stroke patients in Denmark had a CT or MRI scan on the
day of admission, and during hospitalization virtually all
patients were scanned [14]. Regular, structured audits are
conducted nationally, regionally, and locally to ensure data
validity of DAP [13]. In 2011 data-completeness (the number
ofstrokepatientsinDAPcomparedtothenumberofpatients
with hospital admittance registered in the National Patient
Register) was ≥90%, and the number of missing values in
DAP was <10% [14].
2.2. Study Design. All data was provided by DAP. Data
regarding the following items were recorded during hos-
pital stay by treating doctors: discharge diagnosis, date of
admission, atrial fibrillation (yes/no, regardless if previous,
current, paroxysmal, or chronic), and oral anticoagulant
therapy (prescribed, not prescribed without stated reason
or contraindication present). Until approval of dabigatran
etexilatefortheDanishmarketinAugust2011,OACconsisted
of VKA only, and >95% of VKA was warfarin. Only use of
OAC and not the specific product is recorded in the registry;
however, the vast majority of patients were prescribed war-
farin. OAC in patients with AF within 10 days of stroke onset
isaqualityindicator.IfapatienthasAFthetreatingphysician
records if OAC is given; is not initiated in spite of existing
indication or is considered contraindicated. If considered
contraindicated, the cause is indicated by selecting one of
the following: Recent surgery, recent bleeding, thrombocyte
inhibitor treatment mandatory, uncontrolled hypertension,
hemorrhagicdiastase,dementia,alcoholism,patientrejecting
OAC therapy, pregnancy, moribund patient, high fall risk,
previousbleeding,highage,non-compliance,significantliver
failure,kidneyfailure,endocarditisinnativevalves,andlarge
cerebral infarction with edema and/or high bleeding risk.
Dataregardingthefollowingpatientcharacteristicsincluded:
age, sex, alcohol consumption (≤14/21, >14/21 drinks (5g
alcohol) per week for women and men, resp.), smoking
habits (current smoker, occasionally smoker, former smoker,
or never-smoker), marital status (cohabiting, living alone,
or other), type of residence (private home, nursing home,
another form of residence), stroke severity at admission
assessed by the Scandinavian Stroke Scale (SSS) score (0–
58 points) [15], and a history of the following conditions
(yes/no): diabetes mellitus, acute myocardial infarction,
hypertension, and previous stroke. CHADS2 (Congestive
heart failure, Hypertension, Age ≥ 75, Diabetes, Stroke
(doubled)) [16], CHA2DS2-VASc (congestive heart failure,
hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled);
vascular disease, age ≥ 65, sex category (female)) [17], or
HAS-BLED (hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, Labile INR (inter-
national normalized ratio), elderly (e.g., age > 65, frailty,
etc.), and drugs/alcohol concomitantly) [18]s c o r e sw e r en o t
registered.
2.3.StudyPopulation. DatawasobtainedfromDAPcovering
the period from 2003 to 2011. 105,968 patients were included
in the registry. Entries dated before 2003 and after 2011 (𝑛=
116), entries without admission year (𝑛=1 9 ), and patients
aged <18 years (𝑛=2 0 ) were excluded from analysis. Further
analysis was based on patients with a final diagnosis of
ischemic stroke, and consequently 55,551 patients remained
in the analysis. 9,482 patients with AF were identified and
remained in the final analysis.
2.4. Statistical Analysis. All statistical analyses were done
using IBM SPSS Statistics version 20.0.0.
FrequencyanalysiswasusedtoinvestigatetheuseofOAC
in patients with ischemic stroke and AF. Frequency analysis
was used to describe distribution of OAC status, gender, and
strokeseverityaccordingtoage.Characteristicsofpatientsin
therapy and not in therapy were compared using 𝜒
2-test and
Student’s 𝑡-test as appropriate. For categorical variables with
more than two categories (marital status, type of residence,
alcohol consumption, and smoking habits) binary variables
were computed (living alone, institutionalization, excessive
alcohol consumption, and smoking).
Multiple logistic regression analysis was performed to
identify independent predictors of OAC prescription. The
variables included were age (categorized into four groups),
g e n d e r ,s t r o k es e v e r i t ym e a s u r e db yS S Ss c o r e( c a t e g o r i z e d
into four groups), institutionalization, living alone, smok-
ing, excessive alcohol consumption, and a history of dia-
betes, acute myocardial infarction, hypertension, or previous
stroke. 𝑃 values < 0.05 were considered significant.
Values not stated were fused with system missing values,
included in analysis, and reported as missing. In patient
characteristics, missing values were excluded, and the total
valid count for each risk factor is reported.
The study was approved by the Danish Data Protection
Agency, file number 2007-58-0015.
3. Results
3.1. Use of Oral Anticoagulation Therapy. Amongst the 55,551
ischemicstrokepatients,9,482(17.1%)hadAF.Ofthese,3,938
(41.5%) were prescribed OAC; 3,385 (35.7%) were registeredThrombosis 3
Table 1: Characteristics of ischemic stroke patients with AF (𝑛 = 8,782) in and not in OAC.
Characteristics OAC (𝑛 =3 , 9 3 8 ) N oO A C( 𝑛 = 4,844) Total 𝑃 value
Mean (SD) 𝑛 (%) Mean (SD) 𝑛 (%)
Age (years) 76.5 (±9.5) 81.7 (±9.5) 8,782 <0.0001
SSS score (points) 43 (±15) 32 (±18) 8,272 <0.0001
Gender
Female 1,812 (46.0) 2,888 (59.6) 8,782 <0.0001
Male 2,126 (54.0) 1,956 (40.4)
Institutionalized
Yes 193 (5.1) 792 (17.3) 8,354 <0.0001
No 3,591 (94.9) 3,778 (82.7)
Previous stroke
Yes 1,174 (30.7) 1,572 (34.0) 8,447 0.001
No 2,656 (69.3) 3,045 (66.0)
Living alone
Yes 1,629 (42.5) 2,562 (55.2) 8,476 <0.0001
No 2,205 (57.5) 2,080 (44.8)
Smoking
Yes 799 (24.8) 805 (23.6) 6,635 0.232
No 2,420 (75.2) 2,611 (76.4)
Excessive alcohol consumption
Yes 161 (4.7) 184 (5.0) 7,077 0.581
No 3,244 (95.3) 3,488 (95.0)
Diabetes mellitus
Yes 620 (16.1) 759 (16.2) 8,521 0.856
No 3,230 (83.9) 3,912 (83.8)
Acute myocardial infarction
Yes 553 (14.7) 687 (15.4) 8,226 0.431
No 3,200 (85.3) 3,786 (84.6)
Hypertension
Yes 2,247 (59.8) 2,679 (59.3) 8,278 0.668
No 1,513 (40.2) 1,839 (40.7)
as having a contraindication, whilst 1,459 (15.4%) were not
prescribed OAC without a stated reason, and missing values
constituted overall 700 (7.4%). The proportion of patients
in OAC amongst patients without a contraindication was
on average 73.0%, reaching 91.9% in 2011. During the study
period the rates of OAC increased from 36.0 to 46.6%;
the rates of contraindications increased from 18.9 to 42.5%,
whereas the rates of patients not prescribed OAC, without a
stated contraindication,decreased during period from 38.5%
in 2003 to 3.7% in 2011. The amount of missing values
r e m a i n e dt h es a m e .I tw a s6 . 6 %i n2 0 0 3v e r s u s7 . 4 %i n2 0 1 1 .
CharacteristicsofthepatientsinOACandnotinOACare
presented in Table 1. Patients in OAC were younger (mean
age 76.5 ± 9.5 years versus 81.7 ± 9.5 years), had less severe
strokes indicated by higher SSS score (mean score 43 ± 15
points versus 32 ± 18 points), had less often a history of
previousstroke,tendednottolivealone,andweremoreoften
males (𝑃 values < 0.05). Patients in OAC were less often
institutionalized (𝑃 value < 0.05). Alcohol consumption and
smokinghabits,aswellasa historyofdiabetes, hypertension,
or acute myocardial infarction did not differ significantly in
patients with or without prescription of OAC.
The proportionof patients receiving OAC was decreasing
with age, from 56.5% in the age range 51–60 years to 16.4%
intheagerange91–100years.Theproportionofpatientswith
contraindications showed the opposite trend and increased
with age, from 24.1% in the age range 51–60 years to
58.7% in the age range 91–100 years. The proportion of not
prescribed without stated reason and missing values were
only slightly increasing with age from 14.3% and 5.1% in the
age range 51–60 years to 18.2% and 7.3% in the age range
91–100 years, respectively (Figure 1(a)). Amongst ischemic
stroke patients with AF there were more females (5,080)
than males (4,402), and the proportions varied markedly
according to age. The proportion of females increased with
age, from 27.7% in the age range 51–60 years to 75% in
the age range 91–100 years (Figure 1(b)). The stroke severity
markedly increased with age, measured by decreasing SSS
score.Theproportionofmildstrokesdecreasedwithage,with
acorrespondingincreaseinmoderate,severe,andverysevere
strokes (Figure 1(c)).4 Thrombosis
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Oral anticoagulation therapy
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Figure 1: Age distribution of OAC status, gender, and stroke severity in AF patients in the age range of 51–100 years (𝑛 =9 , 3 9 0 ) .
3.2. Independent Predictors of Oral Anticoagulation Therapy.
In the logistic regression model relatively younger age, less
severe stroke, and male gender were significant positive
predictors of OAC prescription, whereas institutionalization,
smoking,andexcessivealcoholconsumptionweresignificant
negative predictors of OAC prescription (𝑃 values < 0.05)
(Table 2). Compared to the oldest age group (>84 years),
likelihood of OAC prescription was almost doubled (OR =
1.984) in the age group 75–84 years, and further increased
(OR = 2.780) in the age group 65–74 years which had similar
o d d s( O R=2 . 7 2 1 )a st h ey o u n g e s ta g eg r o u p( <65 years).
The likelihood was steadily increasing with decreasing stroke
severity (OR = 1.917; 2.468; 3.881, resp.). Male gender was a
weak positive predictor (OR = 1.197). Being institutionalized
was associated with more than halving the likelihood of
receiving OAC (OR = 0.430). Smoking was a weak negative
predictor (OR = 0.871) and excessive alcohol consumption
wasamoderatenegativepredictor(OR=0.692).Livingalone,
or having a history of diabetes, acute myocardial infarction,
hypertension or previous stroke were not independent pre-
dictors of OAC. Patients with missing values were excluded
from analysis; 4,165 (43.9%) had at least one missing value,
and 5,317 (56.1%) patients were included in the final binary
logistic regression.Thrombosis 5
Table 2: Multiple logistic regression analysis of treatment with OAC in ischemic stroke patients with AF (𝑛 =9 , 4 8 2 ) .
𝑃 value OR 95% CI
Age group (years)
>84 Reference category
75–84 <0.0001 1.984 1.716–2.293
65–74 <0.0001 2.780 2.326–3.321
<65 <0.0001 2.721 2.170–3.413
SSS group (points)
Very severe (0–14) Reference category
Severe (15–29) <0.0001 1.917 1.502–2.447
Moderate (30–44) <0.0001 2.468 1.982–3.074
Mild (45–58) <0.0001 3.881 3.170–4.751
Male gender 0.004 1.197 1.058–1.354
Institutionalization <0.0001 0.430 0.337–0.548
Smoking 0.053 0.871 0.756–1.002
Excessive alcohol consumption 0.007 0.692 0.528–0.906
4. Discussion
4.1. Principal Findings. In the present study positive predic-
tors of OAC were relatively younger age, less severe stroke,
and male gender, while negative predictors were excessive
alcohol consumption, smoking, and institutionalization. Age
was one key factor influencing OAC decision. On average
41.5%ofallpatientsadmittedfrom2003to2011withischemic
stroke and AF were prescribed OAC. A majority of patients
n o ti nO A Ch a dac o n t r a i n d i c a t i o n .
4.2. Relations to Other Studies. OAC was administered in
41.5%ofischemicstrokepatientswithAF,inconformitywith
results from a nationwide Swedish registry (Riks-Stroke),
where 11% received primary prevention and 33.5% received
secondary prevention [19] and in line with an American
study of medical records, where 42% of AF patients were
receiving warfarin [8]. In Stockholm Cohort-Study 54% of
AF patients without contraindications received warfarin [7],
whichisasmallerproportionthantheequivalent(73%)inthe
present study. However, the study population in Stockholm
Cohort-Study was different from ours, since not all patients
had ischemic stroke, but other risk factors, as an indication
for OAC. We speculate that the increased focus on atrial
fibrillation during period, as well as the quality indicator
system which directly motivates the treating clinicians to
follow guidelines, may partly explain the high rate (73%) of
patients in relevant OAC.
As it is well known from previous studies, we found that
strokeseverityincreasedwithage[20,21].Femalegenderwas
overrepresented in ischemic stroke patients with AF. Male
gender was more frequent in younger age groups, whereas
female gender was dominating in the oldest patients, in
accordance with that female gender and advanced age are
reported to increase stroke risk in AF patients [4].
I nourmodelthestr ongestp r edictorofO A Cp r escription
was stroke severity, with higher SSS score associated with
higher odds; the more severe the stroke was the less likely
t h ep a t i e n tw a st ob er e c e i v i n gO A C .Th i si si nc o n f o r m i t y
with the finding in Riks-Stroke that being fully conscious
on admission was associated with OAC prescription [19].
In accordance with Riks-Stroke, male gender was a weak
predictor and relatively younger age was a strong predictor
of OAC [19]. Being institutionalized was more than halving
the likelihood of receiving OAC. This is comparable to
Riks-Stroke’s finding that patients with independent ADL
functions before the stroke, and patients being discharged to
homeratherthaninstitution,weremorelikelytoreceiveOAC
[19]. Nursing home residents are presently often severely
disabled and with significant cognitive deficits, as home care
offers extensive help in own home. Institutionalized patients
will consequently often be high risk patients if treated with
OACandthepotentialbenefitoftenwillbeestimatedassmall
by treating physicians and relatives.
In our model comorbidity such as hypertension and
diabetesdidnotpredictOAC,inlinewithStockholmCohort-
Study [7]. Excessive alcohol consumption was a negative
predictor of OAC, as anticipated, since it is considered
arelativecontraindication.Smokingwasanegativepredictor,
however, statistically weak.
4.3. Strengths and Weaknesses. The strengths of the present
study include a population-based design that comprises
the entire Danish population and reflects routine clinical
practice. Health care specialists collected detailed quality
data prospectively, which minimizes the risk of selection and
information bias. Minimal exclusions were made, since the
exclusions of patients with missing data potentially would
have introduced selection bias. Risk of referral bias was low,
s i n c ei tca nbea s s u m edth a tallpa ti e n t swi tha cu t es ym p t o m s
of stroke are referred to the public health care system if
hospitalized. Traditionally hospitalization rates are high after
stroke in Denmark [22].
The weaknesses of the present study include the ret-
rospective design and the risk of misclassifications during
data collection in routine clinical settings. Some change of
practice may have occurred during the 9-year period. How-
ever, participation in DAP is mandatory for all departments6 Thrombosis
treating patients with acute stroke, and extensive efforts are
made to ensure data validity. Missing values in some items
were decreasing during study period, reflecting better imple-
mentation of DAP. Although missing data should always be
a reason for concern, we have no reason to believe these
substantially influenced results, since the missing data were
incidental; however, in some analyses this caused substantial
exclusion of patients. Further, more detailed data on patients
for example, CHA2DS2-VASc score, might have contributed
to a more detailed interpretation of our findings; however,
these data were not collected.
4.4. Perspective. The present study stresses the importance
of continued attention to therapy rates. However, it also
raises the question if alleged underuse of OAC really is
of the previously assumed size or could for a majority be
explained by contraindications and risk/benefit ratios made
bycliniciansonanindividualpatientlevel.Whenthedecision
aboutOACismadeitisimportanttobeknowledgeableabout
present guidelines and actual contraindications, especially
when treating older patients, patients with severe strokes, or
institutionalized patients, which may frequently lead to not
treatingthepatient.Novel OAC (NOAC) drugs such as dabi-
gatran, rivaroxoban, and apixaban show efficacy and safety at
least comparable to warfarin [23–26]. It is difficult to predict
ifNOACwillfurtherincreasetherateofanticoagulationafter
stroke, though efficacy and safety profiles are non-inferior
a n dm o s tl i k e l ys l i g h t l yb e t t e rt h a nw a r f a r i n[ 24–26]; these
drugs also have limitations and the trials did not include
old patients with reduced independency in daily living.
Especially dabigatran etexilate is almost exclusively excreted
by renal pathway, which increases the risk of hemorrhage
in case of acute reduction of renal elimination in case of,
for example, infection and dehydration. Further, there is no
documented antidote to any of the NOACs, whereas pro-
thrombin-complex and vitamin K efficiently and fast can
revert VKA; however, the effect on clinical outcome in VKA-
related intracerebral hemorrhage remains to be documented
[27]. NOACs and other options such as self-monitored
warfarin [28] as alternatives to traditional anticoagulation
practicewillimprovetheoptionsofindividualizingtreatment
andmighttherebycontributepositivelytopatientadherence.
5. Conclusion
In summary, relatively younger age and less severe stroke
were strong positive predictors of OAC. Smoking and exces-
sive alcohol consumption as well as being institutionalized
were negative predictors of OAC. Male gender was a weak
but significant positive predictor. Contraindications were
generallypresentinpatientsnotintherapy.UnderuseofOAC
maybeoverestimatedandrepresentsrisk/benefitestimatesin
individual high-risk patients.
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